AVXL Stock Price, Anavex Life Sciences Quote, Chart

Market Summary

USD3.840.00

Market Closed

0.00%

AVXL Alerts

1 major insider sales recently.

AVXL Stock Price

View Fullscreen

AVXL RSI Chart

AVXL Valuation

Market Cap

315.3M

Price/Earnings (Trailing)

-7.31

Price/Sales (Trailing)

17.7K

EV/EBITDA

-4.79

Price/Free Cashflow

-10.76

AVXL Price/Sales (Trailing)

AVXL Profitability

EBT Margin

-172172.94%

Return on Equity

-31.83%

Return on Assets

-29.15%

Free Cashflow Yield

-9.3%

AVXL Fundamentals

AVXL Revenue

Revenue (TTM)

25.0K

AVXL Earnings

Earnings (TTM)

-43.2M

Earnings Growth (Yr)

33.53%

Earnings Growth (Qtr)

15.02%

Breaking Down AVXL Revenue

Last 7 days

5.2%

Last 30 days

-13.1%

Last 90 days

-31.3%

Trailing 12 Months

-54.3%

How does AVXL drawdown profile look like?

AVXL Financial Health

Current Ratio

3.33

Debt/Equity

3e-6

Debt/Cashflow

-85.0K

AVXL Investor Care

Shares Dilution (1Y)

5.23%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	21.0M	0
2021	31.6M	55.3M	79.1M	50.0M
2020	3.0M	3.7M	7.5M	7.8M
2019	2.8M	1.7M	2.5M	3.0M
2018	0	3.7M	1.6M	2.0M
2017	1.1M	1.5M	2.0M	0
2016	781.4K	758.1K	571.1K	0
2015	0	0	0	776.9K
2013	131.3K	129.2K	176.3K	182.6K
2012	165.4K	150.6K	142.9K	139.2K
2011	91.1K	124.7K	158.2K	180.0K
2010	0	0	24.1K	57.6K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Anavex Life Sciences Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	missling christopher u	acquired	96,861	1.32	73,380	president and ceo
Mar 28, 2024	missling christopher u	sold	-374,972	5.11	-73,380	president and ceo
Jun 29, 2023	missling christopher u	acquired	371,200	1.6	232,000	president and ceo
Jun 28, 2023	missling christopher u	acquired	428,800	1.6	268,000	president and ceo
Jun 28, 2023	missling christopher u	sold	-2,139,310	7.9825	-268,000	president and ceo
May 25, 2022	skarpelos athanasios	sold	-453,000	9.06	-50,000	-
May 25, 2022	skarpelos athanasios	acquired	46,000	0.92	50,000	-
Jun 29, 2021	boenisch sandra	acquired	699,163	4.19424	166,696	pfo and treasurer
Jun 29, 2021	boenisch sandra	sold	-4,422,440	26.53	-166,696	pfo and treasurer
Jun 29, 2021	missling christopher u	sold	-1,342,120	26.00	-51,620	president and ceo

Which funds bought or sold AVXL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Carnegie Capital Asset Management, LLC	reduced	-0.44	-312,510	373,265	0.01%
May 06, 2024	TEACHER RETIREMENT SYSTEM OF TEXAS	reduced	-3.38	-83,000	93,000	-%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-29,140	-	-%
May 06, 2024	Quantbot Technologies LP	new	-	61,080	61,080	-%
May 06, 2024	SG Americas Securities, LLC	sold off	-100	-2,863,000	-	-%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	reduced	-2.3	-46,483	53,292	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	new	-	106,000	106,000	0.01%
May 03, 2024	Larson Financial Group LLC	added	20.3	-3,219	6,184	-%
May 03, 2024	Geneos Wealth Management Inc.	added	10.06	-250,660	378,696	0.02%
May 03, 2024	SIGNATUREFD, LLC	reduced	-39.87	-2,931	1,435	-%

Are Funds Buying or Selling AVXL?

Are funds buying AVXL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVXL

No. of Funds

AVXL Alerts

1 major insider sales recently.

Unveiling Anavex Life Sciences Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.31%	4,360,648	SC 13G/A
Jan 25, 2024	blackrock inc.	8.1%	6,671,075	SC 13G/A
Jan 22, 2024	state street corp	4.44%	3,642,702	SC 13G/A
Feb 09, 2023	vanguard group inc	5.32%	4,144,500	SC 13G/A
Feb 09, 2023	state street corp	7.46%	5,812,605	SC 13G/A
Jan 31, 2023	blackrock inc.	7.2%	5,578,159	SC 13G/A
Feb 09, 2022	state street corp	5.04%	3,834,034	SC 13G
Feb 09, 2022	vanguard group inc	5.05%	3,841,570	SC 13G
Feb 03, 2022	blackrock inc.	6.9%	5,262,666	SC 13G/A
Feb 16, 2021	park west asset management llc	0.0%	0	SC 13G/A

Recent SEC filings of Anavex Life Sciences Corp

View All Filings

Date Filed	Form Type	Document
May 06, 2024	DEFA14A	DEFA14A
May 06, 2024	DEF 14A	DEF 14A
Apr 01, 2024	4	Insider Trading
Mar 28, 2024	144	Notice of Insider Sale Intent
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Anavex Life Sciences Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Anavex Life Sciences Corp News

Latest updates

Anavex Life Sciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2017Q3
Revenue	-	-	-	-	-	-	-	-	-	-	1,269,316	4,519,444	1,319,913	717,328	943,215	738,684	552,335	760,990	413,682	-	1,629,513	-
Operating Expenses	-6.5%	12,652,167	13,530,697	14,189,159	15,384,000	15,284,143	11,723,390	12,252,584	11,398,655	8,954,586	9,396,175	-54,668,603	8,106,479	7,773,189	7,700,703	6,346,219	7,147,175	8,140,037	7,473,517	5,888,990	4,618,013	-
S&GA Expenses	-20.2%	2,591,571	3,247,843	2,882,568	3,317,000	3,902,440	3,066,951	2,879,472	2,434,127	2,233,745	1,470,656	1,402,955	1,381,477	1,720,142	1,352,035	1,635,312	1,388,729	2,061,251	1,761,307	1,481,538	1,620,379	-
R&D Expenses	-2.2%	10,060,596	10,282,854	11,306,591	12,067,000	11,381,703	8,656,439	9,373,112	8,964,528	6,720,841	7,925,519	6,104,906	6,725,002	6,053,047	6,348,668	4,710,907	5,758,446	6,078,786	5,712,210	4,407,452	2,997,634	-
EBITDA Margin	-18619.4%	-1,639	-8.76	-4.64	-3.02	-2.22	-0.63	-0.48	-0.58	-0.90	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	7.1%	1,958,025	1,827,945	1,465,221	1,268,000	704,595	4,910	6,890	11,453	9,216	-1,559	6,977	56,096	70,180	46,720	42,177	34,838	51,465	78,800	83,843	112,226	-
Income Taxes	-256.0%	-63,977	41,000	50,000	-20,000	209,799	29,980	142,731	39,000	26,988	59,281	8,633	4,817	-	9,214	6,116	19,300	48,048	8,717	35,480	-	-
Earnings Before Taxes	9.2%	-10,209,863	-11,238,976	-13,057,279	-12,992,000	-14,080,682	-10,852,387	-11,575,841	-10,141,141	-8,128,234	-7,795,784	-5,956,593	-6,481,805	-7,236,697	-6,582,711	-5,600,302	-6,502,626	-7,198,856	-6,911,014	-5,556,903	-2,849,164	-
EBT Margin	-19372.8%	-1,899	-9.76	-4.99	-3.16	-2.27	-0.63	-0.48	-0.58	-0.90	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	10.1%	-10,145,886	-11,279,976	-13,107,279	-12,972,000	-14,290,481	-10,882,367	-11,718,572	-10,180,141	-8,155,222	-7,855,065	-5,965,226	-6,486,622	-7,236,697	-6,591,925	-5,606,418	-6,521,926	-7,246,904	-6,919,731	-5,592,383	-2,849,164	-
Net Income Margin	-19269.8%	-1,900	-9.81	-5.02	-3.18	-2.29	-0.63	-0.48	-0.58	-0.90	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	23.6%	-5,849,629	-7,652,535	-8,488,579	-5,794,257	-4,044,071	-3,500,955	-7,674,834	-7,520,943	-7,316,845	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-4.1%	148	154	158	159	148	153	160	160	157	162	166	84.00	54.00	35.00	32.00	31.00	31.00	25.00	22.00	21.00	22.00
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32.00	-	-	25.00	22.00	21.00	22.00
Cash Equivalents	-4.8%	144	151	155	153	144	149	153	153	151	152	158	76.00	47.00	29.00	28.00	27.00	27.00	22.00	21.00	19.00	21.00
Liabilities	-0.3%	12.00	13.00	11.00	14.00	13.00	10.00	-	-	-	11.00	9.00	9.00	8.00	7.00	7.00	6.00	6.00	5.00	-	-	-
Current Liabilities	-	-	-	-	-	-	-	9.00	8.00	11.00	11.00	-	8.00	8.00	7.00	7.00	6.00	5.00	5.00	4.00	6.00	5.00
Shareholder's Equity	-4.4%	136	142	147	145	135	142	151	152	146	151	157	76.00	46.00	27.00	25.00	25.00	26.00	20.00	21.00	17.00	19.00
Retained Earnings	-2.9%	-301	-293	-282	-271	-258	-245	-231	-218	-208	-197	-185	-175	-167	-159	-153	-147	-139	-133	-131	-124	-116
Additional Paid-In Capital	0.5%	437	435	430	417	394	388	382	371	355	348	343	251	214	187	178	172	166	154	149	139	133
Shares Outstanding	0.0%	82.00	82.00	81.00	80.00	78.00	78.00	78.00	77.00	76.00	70.00	75.00	70.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	667	-	-	-	921	-	-	-	1,012	-	-	-	177	-	-	-	140	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-25.1%	-7,318	-5,849	-7,652	-8,488	-5,794	-4,044	-7,053	-9,639	-3,500	-7,674	-7,520	-7,316	-7,871	-6,254	-4,044	-5,262	-5,725	-2,534	-7,501	-4,331	-4,160
Share Based Compensation	-28.3%	2,286	3,187	3,867	3,970	5,347	6,042	3,989	4,439	3,909	3,152	2,294	1,846	939	661	1,251	1,701	1,264	1,237	1,234	1,893	2,067
Cashflow From Financing	-97.1%	59.00	2,056	9,003	18,334	258	2.00	6,910	11,836	2,540	2,223	89,222	35,819	25,980	7,885	5,100	4,368	10,998	3,471	9,293	3,074	1,945
Buy Backs	-100.0%	-	1,188	8,535	18,153	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AVXL Income Statement

2023-12-31

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
General and administrative	$ 2,609	$ 3,317
Research and development	8,684	12,067
Total operating expenses	11,293	15,384
Operating loss	(11,293)	(15,384)
Other income
Grant income		25
Research and development incentive income	592	733
Interest income, net	2,008	1,268
Foreign exchange gain	156	366
Total other income, net	2,756	2,392
Net loss before provision for income taxes	(8,537)	(12,992)
Income tax recovery (expense), current	(85)	20
Net loss and comprehensive loss	$ (8,622)	$ (12,972)

AVXL Balance Sheet

2023-12-31

Condensed Consolidated Interim Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023
Current
Cash and cash equivalents	$ 143,765	$ 151,024
Incentive and tax receivables	3,549	2,709
Prepaid expenses and other current assets	756	653
Total Assets	148,070	154,386
Current Liabilities
Accounts payable	4,292	4,322
Accrued liabilities - Note 4	7,286	7,295
Deferred grant income - Note 3	917	917
Total Liabilities	12,495	12,534
Commitments and Contingencies - Note 6
Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share
Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 82,086,511 common shares (September 30, 2023 - 82,066,511)	82	82
Additional paid-in capital	437,184	434,839
Accumulated deficit	(301,691)	(293,069)
Total Stockholders' Equity	135,575	141,852
Total Liabilities and Stockholders' Equity	$ 148,070	$ 154,386

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

CEO	Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
WEBSITE	anavex.com
INDUSTRY	Biotechnology
EMPLOYEES	38

Anavex Life Sciences Corp Frequently Asked Questions

What is the ticker symbol for Anavex Life Sciences Corp? What does AVXL stand for in stocks?

AVXL is the stock ticker symbol of Anavex Life Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anavex Life Sciences Corp (AVXL)?

As of Tue May 07 2024, market cap of Anavex Life Sciences Corp is 315.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVXL stock?

You can check AVXL's fair value in chart for subscribers.

What is the fair value of AVXL stock?

You can check AVXL's fair value in chart for subscribers. The fair value of Anavex Life Sciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anavex Life Sciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVXL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anavex Life Sciences Corp a good stock to buy?

The fair value guage provides a quick view whether AVXL is over valued or under valued. Whether Anavex Life Sciences Corp is cheap or expensive depends on the assumptions which impact Anavex Life Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVXL.

What is Anavex Life Sciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, AVXL's PE ratio (Price to Earnings) is -7.31 and Price to Sales (PS) ratio is 17.67 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVXL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Anavex Life Sciences Corp's stock?

In the past 10 years, Anavex Life Sciences Corp has provided 0.338 (multiply by 100 for percentage) rate of return.